Prognostic Role of Statins in Colorectal Cancer: A Systematic Review and Meta-Analysis

Gang Li's systematic review and meta-analysis, published on figshare in 2026, assesses the association between statin use and survival outcomes in colorectal cancer patients. The analysis includes 25 observational studies with a total of 179,979 patients. It reports hazard ratios for all-cause mortality, cancer-specific mortality, and other outcomes based on statin use before or after diagnosis.

Use Cases

• Conducting secondary analysis of the pooled hazard ratios for all-cause mortality (ACM) and cancer-specific mortality (CSM) reported in the review.
• Comparing the prognostic effects of pre-diagnosis versus post-diagnosis statin use based on the study's findings.
• Evaluating the evidence base for statins and disease-free mortality (DFM) or recurrence-free mortality (RFM) in colorectal cancer.
• Informing the design of future clinical studies on statin use in oncology based on the systematic review's conclusions.

Strengths

• Analysis is based on a substantial patient population of 179,979 individuals from 25 studies.
• Provides specific hazard ratios with 95% confidence intervals for multiple survival outcomes (e.g., ACM: HR 0.80, 95% CI 0.74-0.86).
• Distinguishes between pre-diagnosis and post-diagnosis statin use in its results.

Limitations

• The dataset is a 410.1 KB DOCX file, which is a small document; the underlying raw study data is not included.
• Row count and column-level documentation for any underlying data are unknown.
• The analysis is based on observational studies, which may limit causal inference.

Provenance

Source

figshare, author Gang Li

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, Cochrane Library, and Web of Science.

Time Range

Studies published from database inception until October 31, 2025.

Freshness

Last updated 2026-03-18 05:21:16